| Detected | Trial | Change |
|---|---|---|
| 2026-06-09 | NCT06962800 A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults… |
Trial sites expanded: 97 -> 100 locations |
| 2026-06-09 | NCT07219043 A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney… |
Trial sites expanded: 26 -> 32 locations |
| 2026-06-06 | NCT06685757 A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-06-06 | NCT06685757 A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults… |
Enrollment increased: 120 -> 132 participants |
| 2026-06-06 | NCT06685757 A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults… |
Trial sites reduced: 59 -> 56 locations |
| 2026-05-28 | NCT06935357 A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin… |
Trial sites expanded: 235 -> 239 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06962800 | A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults… | Primary Membranous Nephropathy | Recruiting |
| NCT06935357 | A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin… | Immunoglobulin A Nephropathy (IgAN) | Recruiting |
| NCT07444489 | A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in… | Antibody-mediated Rejection | Enrolling by Invitation |
| NCT06685757 | A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults… | Antibody-mediated Rejection | Active, Not Recruiting |
| Phase 2 | |||
| NCT07219043 | A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney… | Microvascular Inflammation | Recruiting |
| Phase 1 | |||
| NCT06064929 | A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus… | Lupus Nephritis | Active, Not Recruiting |